You are viewing the site in preview mode
Skip to main content
|
Parameters
|
Patients (n = 30)
|
|---|
|
Age (years, mean ± SD) [range]
|
3.6 ± 5.5 [7 days to 17.9 years]
|
|
Sex (n, male:female)
|
22:8
|
|
Etiology of liver disease (%)
|
|
Hepatitis
|
6 (20.0)
|
|
Biliary atresia
|
6 (20.0)
|
|
Non-alcoholic fatty liver disease
|
5 (16.7)
|
|
Others†
|
13 (43.3)
|
|
Serologic Index
|
|
AST (mean ± SD) (IU/L) [range]
|
384.2 ± 577.6 [32–2946]
|
|
ALT (mean ± SD) (IU/L) [range]
|
440.3 ± 655.9 [12–3121]
|
|
APRI (AST to platelet ratio index) (mean ± SD) [range]
|
5.0 ± 8.4 [0.3–42.1]
|
|
AAR (AST to ALT ratio) (mean ± SD) [range]
|
1.3 ± 1.2 [0.2–5.0]
|
|
FIB-4 (fibrosis-4 score) (mean ± SD) [range]
|
0.4 ± 0.8 [0.0–3.9]
|
|
Grade of fibrosis (%)
|
|
F0-1 (none or mild)
|
13 (43.3)
|
|
F2-3 (moderate or severe)
|
17 (56.7)
|
|
Necroinflammatory activity (%)
|
|
A0-1 (none or minimal)
|
18 (60.0)
|
|
A2-3 (mild or moderate)
|
12 (40.0)
|
|
Degree of steatosis (%)
|
|
S0-1 (none or mild < 33%)
|
26 (86.7)
|
|
S2-3 (moderate or severe, ≥ 33%)
|
4 (13.3)
|
- †Progressive familial intrahepatic cholestasis (n = 3), glycogen storage disease (n = 2), hemosiderosis (n = 2), hemophagocytic lymphohistiocytosis (n = 2), autoimmune hepatitis (n = 2), congenital hepatic fibrosis (n = 1), and carnitine palmitoyltransferase I deficiency (n = 1). SD, standard deviation; AST, aspartate aminotransferase; IU, international units; ALT, alanine aminotransferase; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; FIB-4, fibrosis-4 score
